On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at ...

HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

Eisenmenger Complex Management MarketThe global Eisenmenger Complex Management Market is poised for significant growth, projected to exceed USD 12.9 Billion by 2033, up from USD 7.7 Billion in 2023, ...

Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Leerink Partnrs upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. A number ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Copyright ©2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...